Two new studies in IBD genetics show that polygenic risk scores can predict disease severity in Danish patients, and that ancestry-specific variants in Hispanic populations reveal novel risk loci and differential effects of known genes. These findings advance precision medicine by improving risk prediction and highlighting the need for diverse genetic research.
Duvakitug showed durable clinical and endoscopic efficacy over 44 weeks in UC and Crohn's patients in a phase 2b LTE study. The results reinforce duvakitug's potential as a best-in-class TL1A therapy. Both doses were well tolerated.
Teva Pharmaceuticals and Sanofi reported positive Phase 2b long-term extension results for duvakitug, a TL1A-targeting monoclonal antibody, showing durable efficacy over 44 weeks in ulcerative colitis and Crohn's disease patients. UC patients achieved up to 58% clinical remission and CD patients up to 55% endoscopic response at the higher dose.
Teva and Sanofi reported durable 44-week efficacy for duvakitug in inflammatory bowel disease, while the FDA accepted Teva's application for TEV-749, a once-monthly olanzapine injection for schizophrenia.
Edgewise Therapeutics and IDEAYA Biosciences released annual financial reports detailing clinical trial progress and strategic initiatives. Both companies are advancing multiple clinical-stage programs while managing significant operating expenses.
Teva and Sanofi reported positive 44-week data from the RELIEVE UCCD long-term extension study of duvakitug, showing durable efficacy in ulcerative colitis and Crohn's disease patients.
New data from LIBERTY studies show subcutaneous infliximab effectively restored and maintained disease control in Crohn's disease and ulcerative colitis patients after drug holiday of 16 weeks or more, with sustained efficacy through Week 102.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07435779 |
Autologous CAR-T Cell Therapy for Refractory and Relapsing Ulcerative Colitis: A Single-Center Exploratory Study |
RECRUITING | EARLY_PHASE1 |
| NCT02393248 |
Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101) |
TERMINATED | PHASE1/PHASE2 |
